MOTRIN IB (ibuprofen) by Design Pharmaceuticals is cyclooxygenase inhibitors [moa]. First approved in 1984.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
MOTRIN IB is an over-the-counter ibuprofen tablet indicated for pain relief and fever reduction. It works by inhibiting cyclooxygenase enzymes to reduce prostaglandin production and inflammation. This oral NSAID is widely used for minor aches, headaches, and fever in the general population.
As a mature OTC product approaching loss of exclusivity, the brand team is likely focused on cost management and consumer loyalty rather than growth expansion.
Cyclooxygenase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on MOTRIN IB at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDesign Pharmaceuticals is hiring 4 roles related to this product
MOTRIN IB offers limited career growth opportunities due to its mature, LOE-approaching status and minimal linked job availability. Roles on this product are primarily focused on defending market share and optimizing profitability in a competitive OTC category, rather than driving innovation or launch activities.